Practical implication
Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
The European Medicines Agency is enhancing its focus on women's health in medicine by launching initiatives aimed at improving clinical trial representation, developing pregnancy-specific safety assessment methods, and strengthening pharmacovigilance guidelines.
What changed: MAHs and sponsors can expect enhanced requirements for pregnancy-specific safety signals and new methodological guidance for safety studies in pregnant populations.
Why it matters: These initiatives will likely improve drug safety assessments for women, particularly regarding pregnancy and breastfeeding, ensuring better health outcomes for this demographic.
Practical implication: Incorporate enhanced requirements for monitoring pregnancy-specific safety signals into existing pharmacovigilance practices.
View original source
Published from the Firecrawl policy change extraction pipeline.
